Personalized nutrition in ageing society: redox control of major-age related diseases through the NutRedOx Network (COST Action CA16112)

Abstract

A healthy ageing process is important when it is considered that one-third of the population of Europe is already over 50 years old, although there are regional variations. This proportion is likely to increase in the future, and maintenance of vitality at an older age is not only an important measure of the quality of life but also key to participation and productivity. So, the binomial “nutrition and ageing” has different aspects and poses considerable challenges, providing a fertile ground for research and networks. The NutRedOx network will focus on the impact of redox-active compounds in food on healthy ageing, chemoprevention, and redox control in the context of major age-related diseases. The main aim of the NutRedOx network is to gather experts from Europe, and neighbouring countries, and from different disciplines that are involved in the study of biological redox active food components and are relevant to the ageing organism, its health, function, and vulnerability to disease. Together, these experts will form a major and sustainable EU-wide cluster in form of the NutRedOx Centre of Excellence able to address the topic from different perspectives, with the long-term aim to provide a scientific basis for improved nutritional and lifestyle habits, to train the next generation of multidisciplinary researchers in this field, to raise awareness of such habits among the wider population, and also to engage with industry to develop age-adequate foods and medicines.

Keywords:

• Age-related diseases
• cellular organelles diagnostic
• cellular redox signalling
• nutriments-microbiome interactions
• redox active secondary metabolites

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

The NutRedOx Network (COST Action CA16112) is supported by the European Cooperation in Science and Technology (COST). JAT is funded by Instituto de Salud Carlos III [CIBERobn CB12/03/30038] which is co-funded by the European Regional Development Fund. MD is supported by the Novo Nordisk Foundation [grant: NNF13OC0004294]. AF (Universidade Lusófona Research Centre for Biosciences & Health Technologies) acknowledge the financial support from Fundação para a Ciência e a Tecnologia, Portugal [UID/DTP/04567/2016]. CNS acknowledge iNOVA4Health Research Unit [LISBOA-01–0145-FEDER-007344], which is cofunded by Fundação para a Ciência e Tecnologia/Ministério da Ciência e do Ensino Superior, through national funds, and by FEDER under the PT2020 Partnership Agreement and FCT for direct financial support [IF/01097/2013]. LG acknowledges support of the Irish Department of Agriculture, Food and the Marine [FIRM 13 F 354-WheyGSH], Enterprise Ireland and EU Horizon 2020 Marie Skłodowska-Curie grant agreement No 713654 [FoodBIBS MF2018-0151] and by Teagasc [PRO-4-FOOD 0015] and European Regional Development Fund.